Treating PyMT tumor-bearing mice with TZD has little effect on tumor proliferation at the baseline; however, it has powerful anti-proliferative effects against tumors overexpressing ETP [66] and reduces the severity of adverse effects that patients experience in response to insulin-sensitizing PPAR agonists [68]. The gene discussed is INS; the disease is neoplasm.